Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Evercore is most often covered alongside ATG-022, which appears in 1 of these 3 stories. The 19-day window averages about 1.1 stories each week.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Evercore
Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. Evercore is most often covered alongside ATG-022, which appears in 1 of these 3 stories. The 19-day window averages about 1.1 stories each week. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.5 for that window. This profile follows 3 Biotech stories mentioning Evercore across the period from August 5, 2026 to August 23, 2026.
Stories tracked
3
Per week
1.1
Sources per story
2
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 91 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Evercore. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
